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ABSTRACT
An understanding of antibacterial pharmacokinetics and pharmacodynamics is central to setting clinical
breakpoints. It is important to understand any impact that a resistance mechanism may have on these
basic drug properties. With extended-spectrum b-lactamase (ESBL)-producing strains of Enterobacte-
riacae, it is known that MIC, and hence T>MIC, for b-lactams predicts outcome. Therefore,
pharmacodynamic modelling can be used to set breakpoints for ESBL-producing bacteria with
b-lactams.
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INTRODUCTION
The determination of clinical breakpoints for
extended-spectrum b-lactamase (ESBL)-produc-
ing strains of Enterobacteriacae is an essential
element of the laboratory support of antimicrobial
therapy [1]. In addition, appropriate categorisa-
tion of strains as susceptible, intermediate or
resistant to certain agents—especially b-lac-
tams—ensures that appropriate infection control
measures can be taken. A clinical breakpoint
needs to have predictive value in terms of
microbiological and ⁄ or clinical outcomes. Suscep-
tibility has been deﬁned by EUCAST as ‘a level of
antimicrobial activity associated with a high
likelihood of therapeutic success’ (http://
www.EUCAST.org). In contrast, resistance is
deﬁned as ‘a level of antimicrobial activity asso-
ciated with a high likelihood of therapeutic
failure’. If the breakpoint provides these relation-
ships, then infection control and therapeutic
decisions based on laboratory testing are likely
to prevent adverse patient outcome and improve
patient safety, and probably will be cost-effective.
In this article, the development of clinical
breakpoints for b-lactam antibiotics against
ESBL-producing Escherichia coli, Klebsiella spp.
and some other Enterobacteriaceae is discussed.
It is well-known that ESBL producers are often
also resistant to a wide range of other antimicro-
bials, e.g., ﬂuoroquinolones, aminoglycosides and
dihydrofolate reductase inhibitors [2], and these
are not discussed further.
Modern clinical breakpoints depend on three
key areas of information, namely, pharmaco-
dynamics, MIC values and distributions, and
clinical trial data. In order to set a breakpoint
related to a speciﬁc resistance mechanism, several
factors are required:
1. The basic pharmacokinetic (PK) ⁄pharmaco-
dynamic (PD) properties of the drug class
against which the resistance mechanism oper-
ates need to be known.
2. The impact of the resistance mechanism on the
PK ⁄PD relationships of drug concentration
and outcome needs to be established—usually
using in-vitro or in-vivo PD models.
3. It must be determined whether the existing
tools used to decide breakpoints (i.e., models)
are valid for the resistance mechanism.
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4. It must be determined whether the PK ⁄PD
prediction based on in-vitro, in-vivo and in-
silico models can be validated in clinical
trials.
5. It must be determined whether the proposed
PK ⁄PD breakpoints predict microbiolog-
ical ⁄ clinical outcomes in humans.
The PD properties of b-lactams are well-
described. b-Lactams show time-(non-concentra-
tion)-dependent killing within the therapeutic
range, with moderate persistent effects against
Gram-positive bacteria and minimal effects
against Gram-negatives. The goal of dosing is to
maximise the duration of pathogen exposure to
the drug (i.e., to increase the time for which the
drug remains over a threshold value); hence,
T>MIC is regarded as the dominant PK ⁄PD index
[3].
The T>MIC, either in vitro or in vivo (neutrope-
nic murine thigh models) for a static to one log
pathogen kill at 24 h is taken to be most predictive
of outcome in humans. For cephalosporins
against Gram-negatives, this value is c. 25-40%,
while for Gram-positives it is 20-30%. Carbapen-
ems have a lower T>MIC value for a given effect
than do cephalosporins, and if the requirement is
to kill more than one log bacteria, then a higher
T>MIC is needed (Table 1).
Data from the neutropenic murine thigh infec-
tion models obtained using a range of cephalo-
sporins (cefotaxime, ceftriaxone, ceftazidime and
cefepime) to treat bacteria with a range of ESBLs
(TEM-3, TEM-7, TEM-10, TEM-12, TEM-26, SHV-
2, SHV-4, SHV-5, SHV-7, CTX-M) has indicated
that the T>MIC for static or bactericidal effects is
the same, whether or not the strain carries an
ESBL [4]. There are similar data for ertapenem
(Table 2) [5]. In conclusion, these data indicate
that the b-lactam MIC of an ESBL-producing
strain can be used to predict likely human
outcomes from PK ⁄PD models; that is, as long
as a certain T>MIC value is achieved, the micro-
biological outcome can be predicted. The data in
Table 3 illustrate the effect of MIC on the anti-
bacterial effect of ceftriaxone, piperacillin–tazo-
bactam and ertapenem, at standard simulated
human doses, on ESBL producers.
The use of Monte-Carlo simulations is central
to clinical breakpoint determination. Monte-Carlo
analysis is a mathematical tool that allows for
random number generation within a deﬁned
distribution of values. It is used in setting break-
points, as it allows the possible range of PK values
to be modelled and combined. It also allows a
range of MIC values to be modelled. Clearly,
Monte-Carlo analysis is critically dependent on
the quality of the data used to deﬁne the modelled
distributions [6]. If these do not accurately repre-
sent the clinical situation of interest, then the
model will not be predictive. Examples of Monte-
Carlo simulations are shown in Tables 4 and 5 for
ceftriaxone and piperacillin–tazobactam [7]. The
analysis indicates that if the T>MIC target for
ceftriaxone is c. 30%, as indicated by animal
models, then this value will be achieved in
Table 1. The T>MIC antibacterial effect relationship for
Escherichia coli in an in-vitro dilutional model simulating
free drug concentration in humans
Antibacterial effect at
24 h (log CFU ⁄mL)
% T>MIC dosing
for effect with
Ceftriaxone Ertapenem
Static 25 20
)1 log drop 40 25
)2 log drop 55 35
)3 log drop 70 50
)4 log drop 95 70
r2 0.98 0.98
Table 2. The antibacterial effect relationship of ertapenem
against Enterobacteriaceae containing TEM or SHV
b-lactamases in a neutropenic thigh infection model
T>MIC%
Static effect
at 24 h ED5 at 24 h
Extended-spectrum
b-lactamase (ESBL)+
17 ± 17 37 ± 17
ESBL) 21 ± 12 30 ± 23
Table 3. Activity of ceftriaxone (CEF), piperacillin–tazo-
bactam (P-T) and ertapenem (ERTA) at simulated standard
doses against extended-spectrum b-lactamase producers,
studied in an in-vitro pharmacokinetic model
MIC (mg ⁄ L)
Kill at 24 h
(log CFU ⁄mL)
CEF P-T ERTA CEF P-T ERTA
Escherichia coli 1.5 6 0.02 0 )4.2 )4.1
4.0 8 0.06 )2.7 )2.8 )4.1
14.0 20 0.09 +2.1 )0.5 )4.0
Klebsiella
pneumoniae
40.0 28 0.12 +1.8 )1.7 )4.0
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>90% of patients, provided that the ceftriaxone
MIC for the pathogen is £1 mg ⁄L. An equivalent
value for piperacillin–tazobactam is £16 mg ⁄L.
Work by Moczypamba et al. [8] has indicated that,
with a T>MIC target of 20-30%, this value will be
achieved in >99% of patients with standard doses
of imipenem or meropenem against ESBL-pro-
ducing strains. The equivalent value for ertape-
nem was ‡83% of patients.
In conclusion, the use of PK ⁄PD models,
human PKs and Monte-Carlo simulations allow
rational clinical breakpoints to be proposed for
ESBL-producing bacteria. Such proposals form
the basis for discussion, which can be modiﬁed in
the light of MIC distribution and clinical data.
PK ⁄PD modelling indicates that carbapenems
(ertapenem, imipenem and meropenem) are
likely to represent best therapy as a drug class
for all ESBL producers. Other b-lactams are likely
to present adequate therapy, provided that the
strain MICs fall below the PK ⁄PD breakpoint
(Table 6).
How such proposed PK ⁄PD breakpoints are
incorporated into routine clinical microbiology
testing and reporting systems after modiﬁcation
in the light of MIC and clinical data is a subject for
further discussion.
REFERENCES
1. Jacoby GA, Munoz-Price LS. The new b-lactamases. N Engl
J Med 2005; 352: 380–391.
2. Paterson DL, Mulazimoglu L, Casellas JM et al. Epidemi-
ology of ciproﬂoxacin resistance and its relationship to
extended-spectrum b-lactamase production in Klebsiella
pneumoniae isolates causing bacteraemia. Clin Infect Dis
2000; 430: 473–478.
3. Craig WA. Pharmacodynamics of antimicrobials: general
concepts and applications. In: Nightingale CH, Murakawa
T, Ambrose PG, eds, Antimicrobial pharmacodynamics in the-
ory and clinical practice. Basel: Marcel Dekker, 2002; 1–22.
4. Andes D, Craig WA. Treatment of infections with ESBL-
producing organisms: pharmacokinetic and pharmaco-
dynamic considerations. Clin Microbiol Infect 2005; 11 (suppl
6): 10–17.
5. Maglio D, Banevicius MA, Sutherland C, Babalola C,
Nightingale CH, Nicolau DP. Pharmacodynamic proﬁle of
ertapenem against Klebsiella pneumoniae and Escherichia coli
in a murine thigh model. Antimicrob Agents Chemother 2005;
49: 276–280.
6. Ambrose PG, Grasela DM. The use of Monte-Carlo simu-
lations to examine pharmacodynamic variance of drugs:
ﬂuoroquinolone pharmacodynamics against Streptococcus
pneumoniae. Diagn Microbiol Infect Dis 2000; 38: 151–157.
7. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics–
pharmacodynamics of cefepime and piperacillin–tazobac-
tam against Escherichia coli and Klebsiella pneumoniae strains
producing extended spectrum b-lactamases: report from
ARREST Program. Antimicrob Agents Chemother 2003; 47:
1643–1646.
8. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic
modelling of carbapenems and ﬂuoroquinolones against
bacteria that produce extended spectrum beta lactamases.
Clin Ther 2004; 28: 1800–1806.
Table 4. Monte-Carlo simulations and target attainment
rates (TAR) for intravenous ceftriaxone 2 g every 24 h
MIC (mg ⁄L)
TAR at T>MIC rates of
20% 30% 40% 50% 60%
0.25 100 100 97 55 6
0.5 100 100 72 9 0
1.0 100 90 16 0 0
2.0 99 29 1.0 0 0
4.0 54 0 0 0 0
Table 5. Monte-Carlo simulations and target attainment
rates (TAR) for intravenous piperacillin–tazobactam 4 g
every 6 h
MIC (mg ⁄L)
TAR at T>MIC rates of
20% 30% 40% 50% 60%
4 100 100 100 100 99
8 100 100 100 99 83
16 100 100 97 57 9
32 100 83 13 1 0
64 24 2 0 0 0
Table 6. Pharmacokinetic ⁄pharmacodynamic (PK ⁄PD)
systemic breakpoints for representative cephalosporins
and penicillin against extended-spectrum b-lactamase-
producing bacteria
Agent
PK ⁄PD breakpoint
for effective therapy
MIC (mg ⁄L)
Cefotaxime £1
Ceftriaxone £1
Cefepime £4–8
Piperacillin–tazobactam £16
Temocillin £4–8
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